An open-access resource helping scientists to accelerate ALS drug discovery by fostering collaboration, reporting the latest news & sharing research tools.
Joined March 2016
- Tweets560
- Following72
- Followers656
- Likes97
Pinned Tweet
Could a cancer drug targeting PARPs be repurposed as a treatment for #ALS #MND? A growing number of studies @PennMedicine suggest its a possibility. ow.ly/gCgF30n37NV @LeeanneMcgurk @ShorterLab
Could a new technique help sort out the role of microglia in neurodegenerative diseases including #ALS #MND? ow.ly/R2PE30n5orj
Looking to learn more about #ALS #MND but do not have access to a science or medical library? Check out our updated list of open-access reviews of the disease ow.ly/Nktf30n54Ka
Could disease heterogeneity be due to the "shapeshifting" nature of #TDP-43 pathology? A new #FTD study @NatureNeuro suggests its a possibility. ow.ly/WahX30n4UsF #ALS #MND
Looking to present your latest findings in #ALS #MND at an upcoming scientific conference? Check out our 2019 meeting calendar! ow.ly/bk8530n4J8L #ALS #MND
Are you aiming to facilitate clinical testing of potential #ALS #MND therapies by developing strategies to reduce disease heterogeneity? Check out this upcoming funding call @JPNDeurope to support your research ow.ly/E6iz30mXOjd via @The_MRC
Could an emerging test help detect and monitor cognitive decline in neurodegenerative diseases? A new study @JAMANeuro suggests that its a possibility ow.ly/LHJi30mUutN #FTD #ALS
Researchers @MGHNeurology detect glial activation in the spinal cord in addition to the brain in people with #ALS, a key step in developing an imaging-based tool to help evaluate potential immunotherapies in #clinicaltrials #alssymp
Dr Suma Babu, showing us how it's done. Fantastic talk on spinal cord PET imaging biomarkers in #ALS. #alssymp @MGHNeurology @MeritCudkowicz @AtassiNazem
Learn more about this emerging adaptive #clinicaltrial design by checking out this article in @JAMA_current ow.ly/rb5A30mUux1 #ALS #alssymp
Excellent session on #ALS #MND #clinicaltrials today #alssymp moderated by @MeritCudkowicz @LeonardvandBerg -learning from #oncology re: platform trials. Time to bring about a paradigm shift in ALS trials to make the drug development process faster and more efficient
MT @Dr_SharonB #DidYouKnow iPSC lines derived from patients with #ALS and #FTD are now available at @EBiSC_cells @ECACC? cells.ebisc.org/ #alssymp #3A
Learn more about emerging "organ on chip" models that aim to facilitate the development of treatments for neurodegenerative diseases including #ALS by optimizing their ability to enter the CNS ow.ly/m8tu30mTE3J #alssymp #C4
Wondering how changes in the gut could contribute to neurodegenerative diseases including #ALS? Check out this article from our archives ow.ly/OvJi30mTVnj #microbiome #C2 #alssymp
#ICYMI A new partnership sets the stage for clinical testing of the RIPK1 inhibitor #DNL747 in #ALS #MND ow.ly/E4fH30mSs4l @sanofi #necroptosis
Last chance to apply for a research grant @FondationLatran to fund your studies in #ALS #MND Abstracts due: December 6. ow.ly/NEsV30mRB7V
#ICYMI A new pig model may help scientists to further evaluate potential therapies for #ALS #MND, particularly gene therapies. ow.ly/qbyh30mRB2S
Missed the first day of the #stemcell @CellSymposia in Los Angeles, California yesterday? Check out this article from our archives ow.ly/KxWK30mQpDp #ALS #MND
Researchers debate a new strategy to tackle #ALS #MND targeting TDP-43 pathology at the 5th RNA Metabolism in Neurological Disease Conference in San Diego ow.ly/xnqz30mQoFs #stathmin2 #ASO #SfN18